ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.588,56
0,38%
S&P 500
5.479,63
0,12%
US Dollar vs BRL
5,4084
-0,32%
Bitcoin
64.989,86
-2,25%
Brent Oil
84,395
0,59%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. UroGen Pharma Ltd (URGN)

  7. UroGen Pharma Ltd (URGN) Notícias

URGN

UroGen Pharma (URGN)

UroGen Pharma Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:URGN
DataHoraFonteTítuloCódigoCompanhia
17/06/202423:51Business WireUroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:URGNUroGen Pharma Ltd
17/06/202417:46GlobeNewswire Inc.UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:URGNUroGen Pharma Ltd
17/06/202417:19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:URGNUroGen Pharma Ltd
13/06/202411:51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
13/06/202411:45Business WireUroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBCNASDAQ:URGNUroGen Pharma Ltd
11/06/202414:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
11/06/202407:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:URGNUroGen Pharma Ltd
07/06/202409:00Business WireUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:URGNUroGen Pharma Ltd
06/06/202409:00Business WireUroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024NASDAQ:URGNUroGen Pharma Ltd
05/06/202409:00Business WireUroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare ConferenceNASDAQ:URGNUroGen Pharma Ltd
03/06/202409:00Business WireUroGen Pharma Appoints David Lin as New Chief Commercial OfficerNASDAQ:URGNUroGen Pharma Ltd
22/05/202409:00Business WireUroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:URGNUroGen Pharma Ltd
13/05/202409:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:URGNUroGen Pharma Ltd
13/05/202409:00Business WireUroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business HighlightsNASDAQ:URGNUroGen Pharma Ltd
07/05/202409:00Business WireUroGen Pharma to Participate at Upcoming Investor ConferencesNASDAQ:URGNUroGen Pharma Ltd
05/05/202413:20Business WireNew Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction TherapyNASDAQ:URGNUroGen Pharma Ltd
04/05/202416:20Business WireUroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024NASDAQ:URGNUroGen Pharma Ltd
04/05/202412:50Business WireNew Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal TrialNASDAQ:URGNUroGen Pharma Ltd
03/05/202409:00Business WireUroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024NASDAQ:URGNUroGen Pharma Ltd
17/04/202413:02Business WireUroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial CancersNASDAQ:URGNUroGen Pharma Ltd
15/04/202409:00Business WireUroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNASDAQ:URGNUroGen Pharma Ltd
03/04/202409:00Business WireUroGen Pharma Files Patent Infringement Action Against Teva PharmaceuticalsNASDAQ:URGNUroGen Pharma Ltd
14/03/202409:00Business WireUroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102NASDAQ:URGNUroGen Pharma Ltd
04/03/202410:00Business WireUroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024NASDAQ:URGNUroGen Pharma Ltd
26/02/202410:00Business WireUroGen Pharma to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:URGNUroGen Pharma Ltd
12/02/202419:47Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:URGNUroGen Pharma Ltd
24/01/202410:00Business WireUroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102NASDAQ:URGNUroGen Pharma Ltd
17/01/202410:00Business WireUroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial CancersNASDAQ:URGNUroGen Pharma Ltd
11/01/202410:00Business WireUroGen Pharma to Participate in the B. Riley Healthcare ConferenceNASDAQ:URGNUroGen Pharma Ltd
14/11/202318:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:URGNUroGen Pharma Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:URGN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
OIBR3
OI ON
BOV
AZEV4
AZEVEDO PN
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
COGN3
COGNA ON
BOV
PRIO3
PETRORIO ON
BOV
TPIS3
TRIUNFO PART ON
BOV
SGPS3
SPRINGS ON
BOV
JHSF3
JHSF PART ON
BOV
HAGA3
HAGA ON
BOV
TELB4
TELEBRAS PN
BOV
AMAR3
LOJAS MARISA ON
BOV
CSNA3
SID NACIONAL ON
BOV
AMER3
Americanas ON
BOV
QUAL3
QUALICORP ON
BOV
RCSL3
RECRUSUL ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados